BIB vs. NOBL
BIB (ProShares Ultra Nasdaq Biotechnology) and NOBL (ProShares S&P 500 Dividend Aristocrats ETF) are both exchange-traded funds - BIB is a Leveraged Equities fund tracking the NASDAQ Biotechnology Index (200%), while NOBL is a Dividend fund tracking the S&P 500 Dividend Aristocrats Index. Both are passively managed. Over the past 10 years, BIB returned 9.71%/yr vs 9.97%/yr for NOBL. A 0.51 correlation means they provide meaningful diversification when combined. BIB charges 0.95%/yr vs 0.35%/yr for NOBL.
Performance
BIB vs. NOBL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BIB achieves a 12.50% return, which is significantly higher than NOBL's 6.48% return. Both investments have delivered pretty close results over the past 10 years, with BIB having a 9.71% annualized return and NOBL not far ahead at 9.97%.
BIB
- 1D
- 1.97%
- 1M
- 9.49%
- YTD
- 12.50%
- 6M
- 8.62%
- 1Y
- 100.86%
- 3Y*
- 19.65%
- 5Y*
- -0.74%
- 10Y*
- 9.71%
NOBL
- 1D
- 0.68%
- 1M
- 2.27%
- YTD
- 6.48%
- 6M
- 5.98%
- 1Y
- 12.52%
- 3Y*
- 8.50%
- 5Y*
- 6.18%
- 10Y*
- 9.97%
BIB vs. NOBL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 12.50% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
NOBL ProShares S&P 500 Dividend Aristocrats ETF | 6.48% | 6.84% | 6.72% | 8.09% | -6.52% | 25.46% | 8.35% | 27.39% | -3.26% | 21.02% |
Correlation
The correlation between BIB and NOBL is 0.42, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.42 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.53 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.53 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.50 |
Correlation (All Time) Calculated using the full available price history since Oct 10, 2013 | 0.51 |
The correlation between BIB and NOBL shifts across timeframes, from 0.42 (1 year) to 0.53 (5 years), reflecting how their relationship changes across market environments.
BIB vs. NOBL - Sectors Allocation Comparison
Sectors
BIB
NOBL
Healthcare
Financial Services
Basic Materials
-
Communication Services
-
-
Consumer Cyclical
-
Consumer Defensive
-
Energy
-
Industrials
-
Real Estate
-
Technology
-
Utilities
-
Healthcare
BIB
NOBL
Financial Services
BIB
NOBL
Basic Materials
BIB
-
NOBL
Communication Services
BIB
-
NOBL
-
Consumer Cyclical
BIB
-
NOBL
Consumer Defensive
BIB
-
NOBL
Energy
BIB
-
NOBL
Industrials
BIB
-
NOBL
Real Estate
BIB
-
NOBL
Technology
BIB
-
NOBL
Utilities
BIB
-
NOBL
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIB vs. NOBL — Risk / Return Rank
BIB
NOBL
BIB vs. NOBL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and ProShares S&P 500 Dividend Aristocrats ETF (NOBL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIB | NOBL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.41 | ||
| Sortino ratioReturn per unit of downside risk | +1.41 | ||
| Omega ratioGain probability vs. loss probability | 1.36 | 1.19 | +0.17 |
| Calmar ratioReturn relative to maximum drawdown | 5.99 | 1.38 | +4.61 |
| Martin ratioReturn relative to average drawdown | 18.30 | 3.50 | +14.80 |
Loading charts...
Drawdowns
BIB vs. NOBL - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, which is greater than NOBL's maximum drawdown of -35.43%. Use the drawdown chart below to compare losses from any high point for BIB and NOBL.
Loading charts...
Drawdown Indicators
| BIB | NOBL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.24% | -35.43% | -31.81% |
Max Drawdown (1Y)Largest decline over 1 year | -16.92% | -9.11% | -7.81% |
Max Drawdown (3Y)Largest decline over 3 years | -45.30% | -15.36% | -29.94% |
Max Drawdown (5Y)Largest decline over 5 years | -65.86% | -17.92% | -47.94% |
Max Drawdown (10Y)Largest decline over 10 years | -66.20% | -35.43% | -30.77% |
Current DrawdownCurrent decline from peak | -17.29% | -3.29% | -14.00% |
Average DrawdownAverage peak-to-trough decline | -32.71% | -3.48% | -29.23% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.53% | 3.58% | +1.95% |
Volatility
BIB vs. NOBL - Volatility Comparison
ProShares Ultra Nasdaq Biotechnology (BIB) has a higher volatility of 13.56% compared to ProShares S&P 500 Dividend Aristocrats ETF (NOBL) at 3.31%. This indicates that BIB's price experiences larger fluctuations and is considered to be riskier than NOBL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIB | NOBL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.56% | 3.31% | +10.25% |
Volatility (6M)Calculated over the trailing 6-month period | 31.65% | 8.22% | +23.43% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.43% | 11.52% | +28.91% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.60% | 14.38% | +29.22% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.39% | 16.60% | +29.79% |
BIB vs. NOBL - Expense Ratio Comparison
BIB has a 0.95% expense ratio, which is higher than NOBL's 0.35% expense ratio.
Dividends
BIB vs. NOBL - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.55%, less than NOBL's 2.06% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.55% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NOBL ProShares S&P 500 Dividend Aristocrats ETF | 2.06% | 2.14% | 2.05% | 2.09% | 1.94% | 1.89% | 2.14% | 1.89% | 2.37% | 1.74% | 2.13% | 2.02% |
Frequently Asked Questions
BIB and NOBL have a correlation of 0.42, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BIB has higher volatility (13.56%) compared to NOBL (3.31%). In terms of maximum drawdown, BIB dropped -67.24% vs NOBL's -35.43%.
On 10-year performance, NOBL leads with 9.97% vs 9.71% for BIB. On fees, NOBL is cheaper at 0.35% per year. On volatility, NOBL has been the lower-risk option at 3.31%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, NOBL has performed better with a 9.97% return vs 9.71%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
NOBL is cheaper with a 0.35% expense ratio, compared with 0.95% for BIB.
NOBL has the higher dividend yield at 2.06%, compared with 0.55% for BIB.
BIB is categorized as Leveraged Equities, while NOBL is Dividend. BIB tracks NASDAQ Biotechnology Index (200%), while NOBL tracks S&P 500 Dividend Aristocrats Index. Their fees differ too: 0.95% for BIB and 0.35% for NOBL.
BIB currently has the higher Sharpe Ratio (2.51 vs 1.10), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BIB and NOBL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer